The drug, guselkumab, marketed under the brand name Tremfya, was approved Sept. 11, according to the release. The first dose was administered Sept. 17 to a 35-year-old man who has suffered from ulcerative colitis for 13 years.
Tremfya has been used in the past to treat plaque psoriasis and psoriatic arthritis. UChicago Medicine’s David Rubin, MD, led a global study that proved the treatment is also effective for ulcerative colitis. The study was a component of the FDA’s approval of the drug, according to the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
